Company Release no. 21/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 18 December 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
Company Release no. 20/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 06 December 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
Company Release no. 19/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 14 November 2018 Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights Product revenue for first nine months of 2018 was USD 27.8 million, an increase of 101% compared to the same
Company Release no. 18/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 October 2018 Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Ira
Investor News no. 03/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 10 October 2018 Veloxis to Present at the Jefferies 2018 London Healthcare Conference Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that CEO Craig Collard will present
Company Announcement no. 17/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 24 September 2018 Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Morten
Company Release no. 16/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 August 2018 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 August 2018 Veloxis Pharmaceuticals A/S announces, in accordance with
Company Release no. 15/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 23 August 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
Veloxis Upgrades 2018 Outlook Based on Strong Performance Copenhagen, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Highlights Veloxis upgrades 2018 Outlook based on strong performance. Product revenue for first half of 2018 was USD 17.2 million, an increase of 117% compared to the same period last year.
Company Release no. 13/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 July 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and
Veloxis Pharmaceuticals A/S is pleased to announce an ongoing partnership with the American Society of Transplant Surgeons (ASTS) to support the fellowship training of a transplant surgeon with the ASTS-Veloxis Fellowship in Transplantation. The award provides two years of financial support.
Company Release no. 12/2018 To: Nasdaq Copenhagen A/S Copenhagen, Denmark, 16 May 2018 Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 Correction: In the company release titled "Veloxis Pharmaceuticals Announces Financial Results for the
Company Release no. 12/2018 To: Nasdaq Copenhagen A/S Copenhagen, Denmark, 14 May 2018 Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the First Three Months of 2018. This
Company Release no. 11/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 19 April 2018 FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR ® Veloxis Pharmaceuticals A/S announced today that the
Company Release no. 10/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 April 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and
Company Release no. 09/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 April 2018 Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018 Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today, all proposals from the Board of Directors were
Company Release no. 08/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 April 2018 Veloxis Appoints Morten Marott as Chief Financial Officer Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten Marott is joining the company as its new Chief Financial Officer. Mr.
Company Release no. 07/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 March 2018 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2018 Veloxis Pharmaceuticals A/S announces, in accordance with
Investor News no. 01/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 28 March 2018 Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR® Veloxis
Company Release no. 04/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 16 March 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
Veloxis Pharmaceuticals A/S announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant
Company Release no. 2/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 27 February 2018 Veloxis Pharmaceuticals Releases Annual Report for 2017 Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Annual Report for the financial year 2017.
Company Release no. 27/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 December 2017 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2017 Veloxis Pharmaceuticals A/S announces, in accordance with
Company Release no. 25/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 22 December 2017 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and grant
Company Release no. 24/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 01 December 2017 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
Highlights Record product revenue of tUSD 5,924 achieved in Q3 2017. Revenue reached tUSD 22,092 in the first nine months of 2017 representing an increase of 301% compared to the same period last year. U.S. revenue increased 173% to tUSD 10,943 EU revenue increased 89% to tUSD 2,839 RoW upfront
Company Release no. 22/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 October 2017 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and grant warrants to
Company Release no. 21/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 30 September 2017 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 September 2017 Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of
Company Release no. 20/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 20 September 2017 Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Alastair McEwan
Company Release no. 19/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 September 2017 Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis
Company Announcement no. 18 /2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 12 September 2017 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 Highlights Revenue reached tUSD 16,168 in the first half of 2017 representing an increase of 394% compared to the same period last year. U.S.
Company Release no. 16/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 3 July 2017 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 June 2017 Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the
Company Release no. 15/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 21 June 2017 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue
Company Release no. 14/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 June 2017 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
Company Release no. 13/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 06 June 2017 Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China Veloxis Pharmaceuticals A/S today announced that
Investor News no. 04/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 June 2017 Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR ® in Canada COPENHAGAN, DENMARK & DUBLIN,
Highlights It is now estimated that over 6,000 patients in the US and Europe are being treated with Envarsus XR. In the US, prescription growth of Envarsus in the first quarter of 2017 grew 19% vs. the fourth quarter of 2016, in contrast to the -2% decline in total tacrolimus market prescriptions
Company Release no. 11/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 30 April 2017 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 April 2017 Veloxis Pharmaceuticals A/S announces, in accordance with
Company Release no. 10/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 7 April 2017 Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2017 Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today,
Company Release no. 09/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 04 April 2017 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been
Company Release no. 08/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 March 2017 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2017 Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the Danish
Investor News no. 03/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 March 2017 Veloxis Pharmaceuticals A/S Announces Agreement for Taiba Healthcare to Commercialize Envarsus XR in the Middle East and North Africa Region Veloxis Pharmaceuticals A/S
Company Release no. 07/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 28 March 2017 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
Company Release no. 06/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 20 March 2017 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
Company Release no. 05/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 16 March, 2017 Notice to Convene Annual General Meeting 2017 The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the
Please join the event conference 5-10 minutes prior to the start time. You will be asked to provide the confirmation code, speaker name or the title of your conference.
